Claims for Patent: 9,765,298

Summary for Patent: 9,765,298

Title:	Methods and materials for providing cardiac cells
Abstract:	This document provides methods and materials relating to cardiac cells. For example, this document provides methods and materials that can be used to obtain cells having the ability to differentiate into cardiomyocytes. Such cells can be used to repair damaged heart tissue. For example, cells having the ability to differentiate into cardiomyocytes can be used to repair or regenerate heart tissue in patients with a cardiac condition (e.g., ischemic cardiomyopathy, myocardial infarction, or heart failure).
Inventor(s):	Terzic; Andre (Rochester, MN), Behfar; Atta (Rochester, MN)
Assignee:	Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:	11/674,461
Patent Claims:	1. A method for providing heart tissue with cardiopoietic cells capable of differentiating into cardiomyocytes, wherein said method comprises: (a) differentiating adult mesenchymal stem cells lacking expression of CD34 polypeptides into said cardiopoietic cells in vitro by contacting said adult mesenchymal stem cells with a composition under conditions wherein said adult mesenchymal stem cells differentiate into said cardiopoietic cells, wherein said composition comprises at least five molecules selected from the group consisting of TGF-.beta., BMP, TNF-.alpha., IGF-1, FGF-4, IL-6, LIF, VEGF-A, retinoic acid, and .alpha.-thrombin, provided that said composition comprises BMP, .alpha.-thrombin, or TNF-.alpha. when said composition comprises less than six of said molecules of said group; and (b) administering said cardiopoietic cells to said heart tissue, wherein said cardiopoietic cells lack sarcomere formation as evidenced by an absence of a striated immunostaining pattern when stained with an anti-actinin antibody, and wherein said cardiopoietic cells have nuclear localization of Nkx2.5 polypeptides and MEF2C polypeptides. 2. The method of claim 1, wherein said cardiopoietic cells have nuclear localization of GATA4 polypeptides. 3. The method of claim 1, wherein said cardiopoietic cells are human cardiopoietic cells. 4. The method of claim 1, wherein said adult mesenchymal stem cells express CD105, CD166, CD29, and CD44 polypeptides and do not express CD14 and CD45 polypeptides. 5. The method of claim 1, wherein said adult mesenchymal stem cells are human mesenchymal stem cells. 6. The method of claim 1, wherein said adult mesenchymal stem cells are isolated from human bone marrow. 7. The method of claim 1, wherein at least one of said TGF-.beta., BMP, TNF-.alpha., IGF-1, FGF-4, IL-6, LIF, VEGF-A, and .alpha.-thrombin is a human polypeptide. 8. The method of claim 1, wherein each of said TGF-.beta., BMP, TNF-.alpha., IGF-1, FGF-4, IL-6, LIF, VEGF-A, and .alpha.-thrombin is a human polypeptide. 9. A method for obtaining cardiopoietic cells having the ability to differentiate into cardiomyocytes, wherein said method comprises contacting adult mesenchymal stem cells lacking expression of CD34 polypeptides with a composition under conditions wherein said adult mesenchymal stem cells differentiate into said cardiopoietic cells, wherein said composition comprises at least five molecules selected from the group consisting of TGF-.beta., BMP, TNF-.alpha., IGF-1, FGF-4, IL-6, LIF, VEGF-A, retinoic acid, and .alpha.-thrombin, provided that said composition comprises BMP, .alpha.-thrombin, or TNF-.alpha. when said composition comprises less than six of said molecules of said group, wherein said cardiopoietic cells lack sarcomere formation as evidenced by an absence of a striated immunostaining pattern when stained with an anti-actinin antibody, and wherein said cardiopoietic cells have nuclear localization of Nkx2.5 polypeptides and MEF2C polypeptides. 10. The method of claim 9, wherein said cardiopoietic cells have nuclear localization of GATA4 polypeptides. 11. The method of claim 9, wherein said cardiopoietic cells maintain the ability to differentiate into cardiomyocytes for 10 cell divisions if said cardiopoietic cells are contacted with said composition for two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen days and said composition is removed from said cardiopoietic cells after said two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen days. 12. The method of claim 9, wherein said adult mesenchymal stem cells express CD105, CD166, CD29, and CD44 polypeptides and do not express CD14, CD34, and CD45 polypeptides. 13. The method of claim 9, wherein said adult mesenchymal stem cells are human mesenchymal stem cells. 14. The method of claim 9, wherein said composition comprises between 2.5 ng per mL and 10 ng per mL of said TGF-.beta.. 15. The method of claim 9, wherein said composition comprises between 1.times.10.sup.-6 .mu.M and 2.times.10.sup.-6 .mu.M of said retinoic acid. 16. A method for providing heart tissue with cardiopoietic cells capable of differentiating into cardiomyocytes, wherein said method comprises administering said cardiopoietic cells to said heart tissue, wherein said cardiopoietic cells are obtained by contacting adult mesenchymal stem cells lacking expression of CD34 polypeptides with a composition, wherein said composition comprises at least five molecules selected from the group consisting of TGF-.beta., BMP, TNF-.alpha., IGF-1, FGF-4, IL-6, LIF, VEGF-A, retinoic acid, and .alpha.-thrombin, wherein said cardiopoietic cells lack sarcomere formation as evidenced by an absence of a striated immunostaining pattern when stained with an anti-actinin antibody, and wherein said cardiopoietic cells have nuclear localization of Nkx2.5 polypeptides and MEF2C polypeptides. 17. The method of claim 1, wherein said mesenchymal stem cells are in contact with said composition for one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen days.

Details for Patent 9,765,298

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Omrix Biopharmaceuticals Ltd	EVITHROM	thrombin, topical (human)	Solution	125247	08/27/2007		2026-07-24
Omrix Biopharmaceuticals Ltd	EVITHROM	thrombin, topical (human)	For Injection	125247	09/17/2009		2026-07-24